AzTrials
AzTrials

Malnutrition, InfantHOSPIC-6NCT07831343

Hospital-Based Prospective Cohort of Malnutrition Under 6-Month Study (HOSPIC-6-Study)

An observational study of Malnutrition, Infant and Malnutrition, run by Universitas Indonesia at 16 sites in Indonesia.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study is a hospital-based, prospective, multicentre cohort study (the HOSPIC-6 Study) that will follow infants under 6 months of age who are admitted to pediatric or perinatology wards with acute malnutrition, diagnosed according to the 2023 WHO criteria. Read more about this study

Who is it for?
Ages 1 day to 6 months
Conditions the study is for
Malnutrition, Infant, Malnutrition
What is being tested?
Not applicable- observational study
How many people
1,780 participants
Where
16 sitesIndonesia
Study dates
28 Aug 2026to 30 Jul 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 day to 6 months
  • All sexes
  • No healthy volunteers
  • Child

Study population: Infants under 6 months of age admitted to inpatient care in pediatric and perinatology wards at RSCM and partner hospitals/centers that join the HOSPIC-6 collaborative network.

Who may be able to join

  • Infants under 6 months of age admitted to inpatient care who meet the WHO 2023 criteria for acute malnutrition.
  • For infants aged 0-1 month, criteria include a documented weekly weight gain of less than 200 grams, or failure to return to birth weight by 2 weeks of chronological age.
  • For infants aged 1 month to under 6 months, at least one of the following is required:
  • Weight-for-age less than -2 SD
  • Weight-for-length less than -2 SD, or
  • Mid-upper arm circumference under 110 mm (for infants older than 6 weeks), with or without nutritional oedema, and currently receiving treatment for acute malnutrition.
  • Parents or legal guardians must provide written informed consent.

Who cannot join

  • Infants with inborn error of metabolism
  • Infant with syndromic condition (e.g., Down syndrome, Silver-Russell syndrome, Turner syndrome, Klinefelter syndrome, or other diagnosed syndromic conditions),
  • Infant with anatomical abnormality affecting body weight, such as hydrocephalus.
  • Drop Outs Criteria:
  • Participants will be considered "drop-outs" if they are discharged against medical advice or transferred to a non-participating hospital.

Trial locations and contacts

16 sites in 1 country. Contact the study team or a site near you to ask about taking part.

dr. Yoga Devaera, SpA(K), PhD contact

(+62) 8129431861

yoga.devaera@ui.ac.id

dr. Vembricha N Manusita, SpA contact

(+62) 82333 458700

vembricha.nindya@gmail.com

16 sites in 1 country

Indonesia16 sites, 16 recruiting
  • RSUD Abdul Moeleok

    Bandar Lampung, Lampung, 35112

    dr. Arief Rahman, SpA, +62 812 7332 1578, ariefdoctor88@gmail.com

    Arief Rahman, MD, SpA

    Recruiting
  • RSUP Dr. Hasan Sadikin

    Bandung, West Java, 40161

    dr. Viramitha Kusnandi Rusmil, SpA(K), +62 821 2915 9149, virmith@yahoo.com

    Viramitha K Rusmil, MD,SpA(K)

    Recruiting
  • RSUP Sidawangi

    Cirebon, West Java

    dr. Trias K Sari, SpA, (+62) 82145030753, triaskusumasari07@gmail.com

    Trias K Sari, MD, SpA

    Recruiting
  • RSUP Prof. Dr. I.G.N.G. Ngoerah

    Denpasar, Bali, 80113

    Dr. dr. I Gusti Lanang Sidhiarta, SpA(K), +62 822 3682 1069, lanangsidiartha@yahoo.com

    I Gusti L Sidiarta, MD,PhD,SpA(K)

    Recruiting
  • Cipto Mangunkusumo Hospital

    Jakarta Pusat, DKI Jakarta, 10320

    dr. Yoga Devaera, SpA(K), PhD, (+62) 8129431861, yoga.devaera@ui.ac.id

    dr. Vembricha N Manusita, SpA, (+62) 82333 458700, vembricha.nindya@gmail.com

    Recruiting
  • RSIA Bunda Jakarta

    Jakarta Pusat, DKI Jakarta, 10350

    dr. Dimple Nagrani, SpA, (+62) 817811131, dimple.nagrani@gmail.com

    Dimple Nagrani, MD, SpA

    Recruiting
  • RSAB Harapan Kita

    Jakarta Pusat, DKI Jakarta, 11420

    dr. Novitria Dwinanda, SpA(K), +62 81210493502, novitria.dwinanda@gmail.com

    dr. Prajnya Paramitha Narendraswari, +62 812 1215 6238, prajnyaparamitha@gmail.com

    Recruiting
  • RSUD H. Abdul Manap Kota Jambi

    Jambi City, Jambi

    dr. Vivi Septriani, SpA, (+62) 8994478233, viviseptriani@gmail.com

    Vivi Septriani, MD, SpA

    Recruiting
  • RSUD Prof. Dr. W. Z. Johannes Kupang

    Kupang, East Nusa Tenggara, 85111

    Dr. dr. Irene K. L. A. Davidz, SpA., M.Kes, +62 813 4226 9275, irenekathreendavidz@gmail.com

    Irene KLA Davidz, MD,PhD,SpA

    Recruiting
  • RSUD Cideres

    Majalengka, West Java, 45453

    dr. Mohamad Y Anggara, SpA, (+62) 82128119691, yanuaranggara@yahoo.co.id

    Mohamad Y Anggara, MD, SpA

    Recruiting
  • RSUP Prof. Dr. R. D. Kandou

    Manado, North Sulawesi, 95163

    dr. Bobby Pambudi, SpA(K), +62 853-4020-7704, bobby_pam2003@hotmail.com

    Bobby Pambudi, MD, SpA(K)

    Recruiting
  • RSUP Dr. Mohammad Hoesin Palembang

    Palembang, South Sumatra, 30126

    dr. Moretta Damayanti, SpA(K), +62 813 8774 3885, md4eay@gmail.com

    Moretta Damayanti, MD,SpA(K)

    Recruiting
  • RSUD Arifin Achmad Pekanbaru

    Pekanbaru, Riau, 28156

    dr. Mislina Munir, M.Ked(Ped), SpA(K), +6281371720071, ilinmislinamunir@gmail.com

    Mislina Munir, MD,SpA(K)

    Recruiting
  • RSUP Dr. Kariadi Semarang

    Semarang, Central Java, 50244

    dr. Rina Pratiwi, MSi.Med, SpA(K), +62 8122824170, rinapratiwi18@gmail.com

    Rina Pratiwi, MD, SpA(K)

    Recruiting
  • RS Universitas Sebelas Maret

    Sukoharjo, Central Java, 57161

    dr. Maria Galuh Kamenyangan Sari, SpA(K), M.Kes., +62 81225700283, maria.galuh@yahoo.com

    Maria GK Sari, MD,SpA(K)

    Recruiting
  • RSUP Dr. Sardjito

    Yogyakarta, DI Yogyakarta, 55284

    Dr. dr. Neti Nurani, M.Kes, Sp.A (K), +62 821 17231524, neti.nurani@ugm.ac.id

    Neti Nurani, MD,PhD,SpA(K)

    Recruiting

Other trials in Indonesia

About this study

Official title: Acute Malnutrition in Infants Under 6 Months of Age Based on the 2023 WHO Criteria and Influencing Factors: A Multicenter Prospective Cohort in Hospital

This study is a hospital-based, prospective, multicentre cohort study (the HOSPIC-6 Study) that will follow infants under 6 months of age who are admitted to pediatric or perinatology wards with acute malnutrition, diagnosed according to the 2023 WHO criteria. The study will take place at Cipto Mangunkusumo Hospital (RSCM) in Jakarta, Indonesia, together with other hospitals all over Indonesia joining the HOSPIC-6 network, over a period of about one year.

The purpose of this study is to:

Read more
  1. Describe how common acute malnutrition is among infants under 6 months admitted to these hospitals
  2. Observe what happens to these infants during nutrition treatment: whether they recover, whether their growth improves, or whether they experience complications or death.
  3. Look at the factors associated with succesful nutrition therapy outcomes.

After enrolment, each infant's weight, length, head circumference, and mid-upper arm circumference will be measured using standardized techniques, along with information about their birth history, feeding history, and any other illnesses. These measurements, along with details of the nutrition therapy provided, will be repeated on day 3, day 7, and then weekly until the infant is discharged from the hospital. All data will be recorded in a secure, password-protected electronic database (REDCap). No experimental drug or intervention will be given as part of this study; infants will receive the nutrition care that their treating doctors already provide as standard practice, and the study will only observe and record what happens.

The information gathered from this study is expected to help doctors and health authorities better understand the scale of this problem in Indonesia and to support the development of clearer, evidence-based feeding and calorie guidelines for the treatment of acute malnutrition in infants under 6 months of age.

Read the detailed description

Rationale and Scientific Background Acute malnutrition in infants younger than 6 months has historically received less attention than malnutrition in older children, both in global nutrition programs and in national health monitoring systems. The World Health Organization (WHO) 2013 guideline on the management of severe acute malnutrition addressed infants under 6 months only briefly, largely extrapolating recommendations developed for older children. The WHO 2023 guideline expanded this guidance substantially, introducing the broader concept of infants "at risk of poor growth and development" alongside the traditional anthropometric thresholds (weight-for-age, weight-for-length, and mid-upper arm circumference).

National data support the clinical relevance of this population. The 2023 Indonesian Health Survey / Survey Kesehatan Indonesia (SKI) reported a 2.6% prevalence of acute malnutrition among infants aged 0-5 months, and the 2024 Indonesian Nutritional Status Survey / Survei Status Gizi Indonesia (SSGI) reported 1.6% in the same age group - both higher than prevalence figures reported for children 24 months and older. Institutional data from Cipto Mangunkusumo Hospital / Rumah Sakit Ciptomangunkusumo (RSCM) identified 282 infants under 6 months admitted with severe malnutrition in 2024 alone.

Despite this burden, the current WHO 2023 guideline does not specify detailed, concrete caloric targets for nutritional therapy in this age group, and there are no Indonesian studies linking specific nutrition therapy approaches, patient risk factors, and treatment outcomes in this population. This creates uncertainty in day-to-day clinical decision-making and a gap in the evidence needed to develop a standardized, locally relevant treatment protocol. This study (HOSPIC-6) was designed to generate multicenter, prospective, hospital-based evidence to help close this gap.

Research Questions and Objectives

This study is designed to address three research questions:

  1. What is the prevalence of acute malnutrition among infants under 6 months admitted to participating hospitals?
  2. What proportion of infants experience each type of nutrition therapy outcome (successful therapy, death, or improvement in nutritional status)?
  3. What factors are associated with successful nutrition therapy in this population?

The general objective is to characterize the clinical management challenges of acute malnutrition in infants under 6 months. The specific objectives are to determine:

  1. The prevalence of acute malnutrition in this age group,
  2. The proportion of nutrition therapy outcomes among affected infants, and
  3. The factors associated with successful nutrition therapy outcomes.

Hypothesis The investigators hypothesize that the outcome of nutrition therapy in infants under 6 months with acute malnutrition - including growth improvement, treatment success, and survival - is influenced by measurable and identifiable clinical factors (such as gestational history, comorbidities, type of nutritional support received, and achieved daily caloric intake), and that characterizing these factors will help inform more effective, evidence-based treatment strategies.

Study Procedures and Data Collection All infants under 6 months admitted to participating pediatric or perinatology wards will first undergo baseline screening data collection (age, sex, gestational age, weight, length, and mid-upper arm circumference if organomegaly is present). Infants who meet WHO 2023 acute malnutrition criteria and do not meet any exclusion criteria will be enrolled as study subjects after informed consent is obtained; infants who are screened but not enrolled will still have their baseline screening data entered into the study's REDCap database for descriptive purposes.

For enrolled subjects, baseline data collected include anthropometric measurements (weight, length, mid-upper arm circumference, and head circumference obtained using standardized equipment and techniques according to Indonesian Ministry of Health regulation No. HK.01.07/MENKES/51/2022), demographic information, comorbidities, birth history, and nutritional history. Details of the nutrition therapy provided (e.g., breast milk, therapeutic milk such as F-75 or diluted F-100, or infant formula) and available laboratory results are also recorded. Follow-up data collection, including repeat anthropometric measurements, ongoing nutrition therapy details, and available laboratory results, occurs on Day 3, Day 7, and then weekly until the infant is discharged. At each time point, the percentage of estimated daily caloric needs achieved is also recorded.

Registry Infrastructure and Data Management All study data are captured directly into REDCap (Research Electronic Data Capture), a secure, access-controlled electronic data capture platform, using a structured electronic case report form built specifically for this protocol. Use of a single shared REDCap database across all participating sites is intended to standardize data structure and definitions across the multicentre network, rather than relying on site-specific paper records that would later require harmonization.

Data Validation and Quality Assurance The REDCap case report form incorporates field-level validation rules (for example, restricting anthropometric values to clinically plausible ranges and enforcing required fields for key variables such as enrollment eligibility criteria) to reduce data entry error at the point of capture. The principal investigator's team performs centralized data verification and cleaning of records entered into REDCap on an ongoing basis, cross-checking entries for internal consistency (for example, agreement between recorded eligibility criteria and enrollment status) and following up directly with local investigators when discrepancies, implausible values, or missing critical fields are identified.

Roles and Responsibilities The principal investigator team is responsible for developing and maintaining the study protocol, the REDCap database structure, and the ethics/regulatory documentation, as well as for centralized data verification and cleaning. Local investigators at each participating site are responsible for obtaining local research permits, ensuring anthropometric equipment at their site is available, calibrated, and used according to the standard operating procedure specified in the protocol, ensuring eligible subjects are identified and enrolled consecutively according to protocol, obtaining informed consent, and entering (or supervising the entry of) subject data into REDCap in a timely manner. This division of responsibilities functions as the study's core standard operating procedure for recruitment, data collection, and data management across sites; coordination between the principal investigator team and local investigators occurs as needed throughout enrollment and follow-up to resolve site-level questions or data queries.

Source Data Verification. Data entered into REDCap are expected to be traceable to source documentation at each site (hospital medical records and/or paper case report forms completed at the bedside at the time of measurement), allowing source data verification and consistency checks against the electronic record as part of routine data cleaning.

Data Dictionary A structured data dictionary underlies the REDCap database, defining each variable collected (for example, anthropometric measures, nutrition therapy type, and outcome classification), its permitted values or coding scheme, and its collection time point, to ensure consistent interpretation and entry of each field across all participating sites.

Handling of Missing Data Because this is an observational, hospital-based cohort in which not every laboratory test or measurement is routinely available for every infant at every time point (for example, laboratory results are recorded only when clinically obtained as part of standard care), some degree of missing data is anticipated, particularly for laboratory variables, rather than for core anthropometric measurements, which are collected prospectively as part of the study procedure at each scheduled time point. Data queries generated during centralized cleaning (for missing, out-of-range, or internally inconsistent entries) are routed back to the responsible local investigator for resolution against source documentation where possible. Where a data point remains genuinely unavailable (for example, a laboratory test not clinically indicated or not performed), it is recorded as missing rather than imputed at the point of data entry. The approach to handling such missingness in the final analytic dataset (for example, complete-case analysis for the specific variable, or descriptive reporting of missingness) will be determined at the analysis stage according to the extent and pattern of missingness observed for each variable, following standard descriptive and analytic conventions for observational cohort data.

Statistical Analysis Plan Descriptive statistics will be used to characterize the screened and enrolled populations and to estimate the prevalence of acute malnutrition among infants under 6 months admitted to participating hospitals with corresponding proportions reported for each nutrition therapy outcome category (treatment success, death, and improvement in nutritional status). Continuous variables such as, anthropometric measures and estimated caloric intake will be summarized as means with standard deviations or medians with interquartile ranges, depending on their distribution, and categorical variables will be summarized as frequencies and percentages. Bivariate comparisons between infants with successful versus unsuccessful nutrition therapy outcomes will be conducted using chi-square or Fisher's exact tests for categorical variables and t-tests or non-parametric equivalents for continuous variables, as appropriate to the data distribution. Factors independently associated with successful nutrition therapy outcomes will be assessed using multivariable regression analysis (logistic regression), adjusting for clinically relevant covariates such as gestational history, comorbidities, and achieved caloric intake. A two-sided p-value of less than 0.05 will generally be considered statistically significant, and results will be reported with corresponding effect estimates and 95% confidence intervals.

Significance As a purely observational, hospital-based registry-style cohort with no experimental intervention, HOSPIC-6 is designed to generate real-world, multicenter evidence on the epidemiology and treatment outcomes of acute malnutrition in infants under 6 months in Indonesia. Its centralized REDCap infrastructure, standardized measurement procedures, and structured data verification process are intended to support data quality across a multicenter, resource-varied hospital network. Findings are expected to inform the development of a more detailed, locally relevant clinical pathway - including specific caloric targets - for the management of acute malnutrition in this age group, both at network hospital and more broadly within the Indonesian health system.

Being tested
Not applicable- observational study
Keywords
Malnutrition, Infant, Acute Malnutrition, Wasting, Nutritional Oedema, Nutritional Therapy, Anthropometry, Mid-Upper Arm Circumference, Treatment Outcome, Prospective Cohort Studies, Infant Under 6 months
Medical subject headings
Infant Nutrition Disorders, Malnutrition, Cachexia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Not applicable- observational studyOther

    No intervention (observational study)

Study groups in NCT07831343
Study groupRoleWhat they receive
Infants Under 6 Months of Age with Acute Malnutrition based on WHO 2023 GuidelineInfants under 6 months of age fulfilling acute malnutrition criteria based on WHO 2023
Receives: Other: Not applicable- observational study

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in nutritional status

    Change in nutritional status as indicated by change in z-score toward the age- and sex-specific reference, as determined using the PediTools online calculator. The 24-week upper bound is to accommodate prolonged hospitalization in infants with severe comorbidities requiring extended nutritional stabilization.

    Measured: Baseline, Day 3, Day 7, and weekly thereafter through hospital discharge, up to 24 weeks, whichever comes first.

Secondary outcomes (1)
  1. All-cause mortality

    Proportion of infants under 6 months with acute malnutrition who died from any cause during hospitalization.

    Measured: From baseline until death or hospital discharge, up to 24 weeks.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Sep 2026
  2. Study start28 Aug 2026
  3. Primary completion30 Jul 2027 (estimated)
  4. Study completion30 Jul 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,780 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07831343
Sponsor's protocol ID
KET-1099/UN2.F1/ETIK/PPM.00.02
Acronym
HOSPIC-6
Status last verified
Oct 2026
First submitted
31 Aug 2026
Last updated
2 Nov 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Anonymized individual participant data collected in this study (HOSPIC-6 Study) may be made available to other researchers upon reasonable request to the principal investigator.

Questions about this trial

What is this clinical trial studying?

An observational study of Malnutrition, Infant and Malnutrition, run by Universitas Indonesia at 16 sites in Indonesia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 16 sites in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact dr. Yoga Devaera, SpA(K), PhD ((+62) 8129431861, yoga.devaera@ui.ac.id), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in nutritional status (time frame: Baseline, Day 3, Day 7, and weekly thereafter through hospital discharge, up to 24 weeks, whichever comes first.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in